

CLEC12A/MICL/CLL-1

Catalog # PVGS1821

Product Information

Primary Accession Species	Q5QGZ9-2 Human
Sequence	His65-Ala265
Purity	> 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
Endotoxin Level	Less than 1EU per μ g by the LAL method.
Biological Activity	Immobilized CLEC12A/MICL/CLL-1 hFc Chimera, Human (Cat.No.: Z03958) at 0.5 μ g/ml (100 μ l/Well) on the plate can bind Biotinylated Anti-CLEC12A Antibody, hFc Tag
Expression System	HEK293
Theoretical Molecular Weight	50.9 kDa
Formulation Reconstitution	Lyophilized from a 0.22 μ m filtered solution in PBS, (pH 7.4). It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH ₂ O more than 100 μ g/ml.
Storage & Stability	Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Additional Information

Target Background	CLEC12A, also known as CLL-1 is inhibitory C-type lectin-like receptor with ITIM motif. It can associate with signaling phosphatases SHP-1 and SHP-2. CLEC12A is a potential target due to its high expression in acute myeloid leukemia (AML) cells. And there are various therapeutic approaches using CLEC12A as a target for AML, such as CD3/ CLEC12A antibody. It can recruit unstimulated primary T cells against cancer cells with CLL-1 on the surface.
--------------------------	--

Protein Information

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.